Literature DB >> 10376457

Value of brush cytology for dominant strictures in primary sclerosing cholangitis.

C Y Ponsioen1, S M Vrouenraets, A W van Milligen de Wit, P Sturm, M Tascilar, G J Offerhaus, M Prins, K Huibregtse, G N Tytgat.   

Abstract

BACKGROUND AND STUDY AIMS: Around 10% of patients with primary sclerosing cholangitis (PSC) develop cholangiocarcinoma, which is cholangiographically often indistinguishable from a benign dominant stricture. The aim of the present study was to assess the value of brush cytology in discriminating between benign and malignant dominant strictures in primary sclerosing cholangitis. PATIENTS AND METHODS: The results of all brush cytology specimens from dominant strictures from patients with established primary sclerosing cholangitis, taken at endoscopic retrograde cholangiopancreatography between 1987 and 1996, were compared with the histological diagnosis or clinical status of the patients at least 2 years later.
RESULTS: A total of 47 brush cytology samples, taken between 1987 and 1996, from 43 PSC patients could be included. Between 1993 and 1996, p53 immunocytochemical examination was done in 27 brush cytology specimens and K-ras mutation analysis in 25 patients. The sensitivity, specificity, positive predictive value, and negative predictive value of brush cytology for detection of malignancy were 60%, 89%, 59%, and 89%, respectively. These figures were not improved by adding the results of p53 and K-ras analysis. Logistic regression analysis did not reveal any additional benefit of p53 or K-ras analysis either. Prior stenting did not adversely affect specificity.
CONCLUSIONS: The sensitivity and positive predictive value of brush cytology for dominant strictures in PSC are rather poor. The specificity and negative predictive value are reasonably good. There was no additional value from p53 immunocytochemistry and K-ras mutation analysis. Prior stenting did not affect the results.

Entities:  

Mesh:

Year:  1999        PMID: 10376457     DOI: 10.1055/s-1999-18

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  25 in total

Review 1.  Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis.

Authors:  Adolf Stiehl; Daniel Rost
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 2.  [Influence of technical advancements on the management of biliary tract diseases].

Authors:  Andreas Püspök
Journal:  Wien Med Wochenschr       Date:  2006-07

Review 3.  Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis.

Authors:  Murad Aljiffry; Paul D Renfrew; Mark J Walsh; Marie Laryea; Michele Molinari
Journal:  HPB (Oxford)       Date:  2011-02       Impact factor: 3.647

Review 4.  Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

Authors:  Domenico Viterbo; Valerie Gausman; Tamas Gonda
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

Review 5.  Update of endoscopy in liver disease: more than just treating varices.

Authors:  Christoforos Krystallis; Gail S Masterton; Peter C Hayes; John N Plevris
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

6.  DNA flow cytometric analysis of paraffin-embedded tissue for the diagnosis of malignancy in bile duct biopsies.

Authors:  Hannah Lee; Peter S Rabinovitch; Aras N Mattis; Sanjay Kakar; Won-Tak Choi
Journal:  Hum Pathol       Date:  2020-04-06       Impact factor: 3.466

Review 7.  Cholangiocarcinoma: has there been any progress?

Authors:  Judith Meza-Junco; Aldo J Montano-Loza; Mang Ma; Winnie Wong; Michael B Sawyer; Vincent G Bain
Journal:  Can J Gastroenterol       Date:  2010-01       Impact factor: 3.522

Review 8.  [Primary sclerosing cholangitis].

Authors:  A Stiehl
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

Review 9.  Diagnosis and treatment of cholangiocarcinoma.

Authors:  Kirsten Muri Boberg; Erik Schrumpf
Journal:  Curr Gastroenterol Rep       Date:  2004-02

10.  Treatment of primary sclerosing cholangitis.

Authors:  Daniel Rost; Hasan Kulaksiz; Adolf Stiehl
Journal:  Curr Treat Options Gastroenterol       Date:  2007-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.